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Dyslipidemia among HIV/AIDS patients
receiving antiretroviral therapy: A prospective
observational study
A. Biswas ∗, K. Suneesh, P. Sohal, S. Sharma
AIIMS, New Delhi, India
Background: Dyslipidemia due to Antiretroviral Therapy
among HIV/AIDS increases cardiovascular risk and high morbidity
and mortality. This study was conducted to estimate the incidence
of dyslipidemia for prevention, control and proper management to
reduce cardiovascular risks and death.
Methods & Materials: We conducted a prospective observa-
tional study among HIV/AIDS patients those who were initiated
Antiretroviral Therapy (ART) medication. The US NCEP III (National
Cholesterol Education Program– III) guidelineswere used to deﬁne
dyslipidemia. Fasting Lipid proﬁle was estimated at 0 month, 6th
month and at 12th month from the date of enrolment. Our primary
observationwas to determine the change in fasting serum lipid lev-
els higher than border line as per the NCEP-III guideline. We used
linear regression to experience change in lipid levels controlling for
base line lipid values, demographic and clinical characteristics.
Results: We enrolled 135 patients for the study. There were
65.9% (89) male,34.1% (46) female, mean age 37 years(SE-0.8)
and 6.7% (9) were unmarried. Most of the patients 63.7% (86)
had heterosexual transmission. 22.96% (31) had unknown history
and 12.6% (17) through blood transfusion. In our study 3 drugs
combination ART was given and 30% (40) of the these were receiv-
ing Stavudine based ART regimen(d4T+3TC+NVP/EFV), 70%(95)
Zydovudine based regimen (AZT+3TC+NVP/EFV). Overall inci-
dence of dyslipidemia (high total cholesterol > 239mg/dl) was 25%
(26). Among Stavudine based regimen 15%(6) had incidence of
dyslipidemia (high cholesterol). Incidence of dyslipidemia was
detected among 22.8% (23) due to high LDL-C (>159mg/dl). Among
Stavudine based regimen 17.5% (7) of patients developed dys-
lipidemia (high LDL-C). High triglyceride (TG>299mg/dl) was
detected among 8.2% (9). Totalmortalitywas 6.6% (9), lost to follow
up were 11.8% (16). At 6 months of follow up 6 (5%) patients devel-
oped dyslipidemia (high cholesterol) and were referred for the
management with lipid lowering agents.
Conclusion: Incidence ofDyslipidemia at 6thmonthwas 5% and
at 12th month was 25% .The incidence of high LDL-C was 22.8%,
among Stavudine regimen was 17.5% and high TG was 8.2% over
one year with ART. However in our study Stavudine based regimen
was found to have 15% incidence of dyslipidemia.
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Ion PGM deep sequencing improves mutation
detection in infants who failed PMTCT
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Background: In children who are HIV-infected despite a nevi-
rapine (NVP) containing HIV-PMTCT regimen, bulk sequencing
reliably detects major variant drug resistance mutations (DRM)
(>20-30% of viral population). Ion Personal Genome Machine
(Ion PGM) deep sequencing, combined with rigorous analysis and
error correction may be an alternative with increased sensitivity,
enabling detection of potentially clinically signiﬁcantminor DRM
variants.
Methods & Materials: We conducted a retrospective study
in 20 HIV-infected infants, born from Oct 2006 to Oct 2009,
who failed PMTCT (maternal AZT from 28 weeks gestation, intra
partum NVP, and neonatal single doseNVP with 7 days, AZT).
Baseline specimens, before combination antiretroviral therapy
(cART), werebulk sequenced using in-house genotyping. For Ion
PGM sequencing, extractedRNA was reverse transcribed using
random pentadecamers, before ampliﬁcation through 14 pre-
and 7-nested PCR’s. PCR products were enzymatically fragmented
and ligated to indexingbar-codes, followed by enrichment and
sequencing. Reads wereﬁltered using quality scores, aligned to a
subtype C reference sequence using a codon-aware versionof the
Smith-Waterman algorithm, correcting for homopolymer errors. A
mixture of multinomials probabilisticmodel was used to distin-
guish sequencing error from true minor variants with posterior
probabilities≥99.99%, excluding bases identiﬁed as errors. For each
sample, we computed the mean of all pairwise Tamura-Nei 93 dis-
tances between reads with at least 100 overlapping base pairs to
quantify nucleotidediversity.
Results: Median age was 3.5 (IQR: 2.4-4.8) months, median
viral load and CD4% was 5.8 log copies/ml (IQR: 5.1-6.3) and
26% (IQR: 22-35%) respectively; 65% were female. Median cov-
erage for reverse transcriptasepositions 40 - 230 (including all
major ARV-DRM) was 31000 (IQR: 20400-39500) and median
intra-samplenucleotide diversity was 0.6% (IQR: 0.4%-1.2%). Bulk
sequencing detected one NNRTI DRM in 2 patients: K103N and
Y181I. Ion PGM detected DRM at a frequency ≥ 2% in 2 addi-
tional patients: K103N (22%) andY181C (2%), respectively, and
minor variant Y181C (3.7%) in addition to K103N (detected
by bulk sequencing) in a third. No AZT-associated DRM were
detected.
Conclusion: Only 20% of infants had NVP associated DRM
≥2% frequency by deep sequencing. When combined with a
bioinformatic pipeline, Ion PGM deep sequencing detected more
NVP-DRMs in infants with PMTCT exposure than bulk sequenc-
ing. Thismethod could be valuable when considering recycling
